

Cochrane Database of Systematic Reviews

Recombinant human interleukin 10 for induction of remission in Crohn's disease (Review)

Buruiana FE, Solà I, Alonso-Coello P

Buruiana FE, Solà I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2010, Issue 11. Art. No.: CD005109. DOI: 10.1002/14651858.CD005109.pub3.

www.cochranelibrary.com



TABLE OF CONTENTS

ABSTRACT1	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	5
OBJECTIVES	5
METHODS	5
RESULTS	6
Figure 1	7
Figure 2	8
Figure 3	8
Figure 4.	9
Figure 5.	9
Figure 6.	9
DISCUSSION	9
AUTHORS' CONCLUSIONS	0
ACKNOWLEDGEMENTS	0
REFERENCES	1
CHARACTERISTICS OF STUDIES	1
DATA AND ANALYSES	5
Analysis 1.1. Comparison 1 IL-10 vs placebo, Outcome 1 Complete remission (CDAI<150 with a decrease in CDAI of at least 100 16 points from baseline).	6
Analysis 1.2. Comparison 1 IL-10 vs placebo, Outcome 2 Clinical remision (CDAI<150).	6
Analysis 1.3. Comparison 1 IL-10 vs placebo, Outcome 3 Serious adverse events.	6
Analysis 1.4. Comparison 1 IL-10 vs placebo, Outcome 4 Any adverse event	7
Analysis 1.5. Comparison 1 IL-10 vs placebo, Outcome 5 Withdrawals due to adverse events.	7
Analysis 1.6. Comparison 1 IL-10 vs placebo, Outcome 6 Thrombocytopenia	7
Analysis 1.7. Comparison 1 IL-10 vs placebo, Outcome 7 Severe adverse events	8
WHAT'S NEW	8
CONTRIBUTIONS OF AUTHORS	8
DECLARATIONS OF INTEREST	8
SOURCES OF SUPPORT	8
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	8
INDEX TERMS	8



[Intervention Review]

Recombinant human interleukin 10 for induction of remission in Crohn's disease

Felicia Elena Buruiana¹, Ivan Solà², Pablo Alonso-Coello³

¹Core Surgical Training 1, Princess Alexandra Hospital, Harlow, UK. ²Iberoamerican Cochrane Centre, Institute of Biomedical Research (IIB Sant Pau), Barcelona, Spain. ³Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona, Barcelona, Spain

Contact: Pablo Alonso-Coello, Iberoamerican Cochrane Centre, Institute of Biomedical Research Sant Pau (IIB Sant Pau), Barcelona, CIBER Epidemiología y Salud Pública (CIBERESP), Spain, Sant Antoni Maria Claret 171 (Casa de Convalescencia), Barcelona, 08041, Spain. palonso@santpau.cat, alonsocoello@gmail.com.

Editorial group: Cochrane IBD Group. **Publication status and date:** Edited (no change to conclusions), published in Issue 1, 2012.

Citation: Buruiana FE, Solà I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2010, Issue 11. Art. No.: CD005109. DOI: 10.1002/14651858.CD005109.pub3.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

The etiology of Crohn's disease remains unknown, nevertheless, it is apparent that inflammation is associated with an imbalance between proinflammatory and anti-inflammatory cytokines produced within the intestinal mucosa. Crohn's disease represents a state of dysregulated inflammation and drugs that can augment the anti-inflammatory response have the potential to downregulate inflammation and thereby improve the disease. The efficacy of recombinant IL-10 in Crohn's disease was first demonstrated in a pilot study. Since then other trials have evaluated its efficacy but the available evidence has not been systematically reviewed.

Objectives

To determine the efficacy and tolerability of recombinant human interleukin 10 (IL-10) for induction of remission in Crohn's disease.

Search methods

A computer assisted search of the Cochrane Central Register of Controlled Trials and the Cochrane IBD/FBD Review Group Specialized Trials Register and the on-line databases MEDLINE and EMBASE was performed to identify relevant publications up to September 2010. Reference lists were searched and the pharmaceutical industry and experts were contacted to identify additional studies.

Selection criteria

Randomized controlled trials comparing recombinant human interleukin 10 to a placebo or control therapy for the treatment of patients with active Crohn's disease were included.

Data collection and analysis

All publications identified by the search strategy were assessed independently by two authors, and relevant studies selected according to the inclusion criteria. The risk of bias of each included study was assessed independently by two authors. Data were analyzed using Review Manager (RevMan 5). A random effects model was used for pooling of data. All data were analyzed on an intention-to-treat basis. Heterogeneity among studies was assessed using the chi-square test and the I² statistic.

Main results

The risk of bias in the included studies was low. The overall quality of the evidence based on the GRADE approach was moderate. No statistically significant differences were found between interleukin 10 and placebo for complete remission (CDAI \leq 150 with a 100 point



decrease in CDAI from baseline; RR=1.43; 95% CI 0.62 to 3.29; $I^2=40\%$) or clinical remission (CDAI \leq 150; RR=1.29; 95% CI 0.79 to 2.11; $I^2=0\%$). Patients treated with interleukin 10 were significantly more likely to withdraw from the studies due to adverse events (RR=13.50; 95% CI 3.89 to 46.79; $I^2=0\%$).

Authors' conclusions

Interleukin 10 does not appear to provide any benefit for the treatment of active Crohn's disease. This systematic review shows that interleukin 10 does not increase the number of remissions (complete or clinical), but increases the rate of withdrawal due to adverse events relative to placebo. The quality of the evidence regarding the efficacy of IL-10 is moderate and although further research may have an impact on point estimates of efficacy further randomized trials are unlikely to be undertaken.

PLAIN LANGUAGE SUMMARY

Interleukin 10 (IL-10) for induction of remission in Crohn's disease

Crohn's disease is an inflammatory condition of unknown origin that can affect any portion of the gastrointestinal tract from the mouth to the anus. However, it most commonly involves the distal small bowel and/or the colon. Interleukin 10 does not appear to provide any benefit for the treatment of active Crohn's disease. This systematic review showed that this drug does not increase the number of remissions but increases the number of patients that withdrew from the included studies due to side effects. The methodological quality of the included studies was high. Further studies of this agent for the treatment of active Crohn's disease are unlikely to be undertaken.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. IL-10 compared to placebo for induction of remission in Crohn's disease

IL-10 compared to placebo for induction of remission in Crohn's disease

Patient or population: patients with induction of remission in Crohn's disease Settings:

Intervention: IL-10

Recombinant human interleukin 10 for induction of remission in Crohn's disease (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: placebo

Outcomes	Illustrative comparativ	e risks* (95% CI)	Relative effect (95% CI)	No of Partici- pants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk		(studies)	(GRADE)	
	placebo	IL-10				
Complete remission (CDAI<150 with a de-	Study population		RR 1.43 (0.62 to 3.29)	470 (3 studies)	$\oplus \oplus \oplus \odot$ moderate ¹	
crease in CDAI of at least 100 points from baseline)	137 per 1000	196 per 1000 (85 to 451)	(0.02 to 5.25)			
·	Medium risk populatior	1				
	167 per 1000	239 per 1000 (104 to 549)				
Clinical remision (CDAI<150)	Study population		RR 1.29 (0.79 to 2.11)	470 (3 studies)	⊕⊕⊕⊙ moderate ²	
(147 per 1000	190 per 1000 (116 to 310)	(0110 to 2112)	(0 5000105)	moderate	
	Medium risk populatior	1				
	182 per 1000	235 per 1000 (144 to 384)				
Withdrawls due to ad- verse events	Study population		RR 13.5 (3.89 to 46.79)	228 (2 studies)	⊕⊕⊕⊝ moderate ³	
	22 per 1000	297 per 1000 (86 to 1000)	(0.05 to +0.15)		mouerale	
	Medium risk populatior	1				

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Recombinant human interleukin 10 for induction of remission in Crohn's disease (Review)

15 per 1000

202 per 1000 (58 to 702)

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Sparse data: only 79 events observed. Altough for this outcome we observed a moderate heterogenity (I square=40%), we decided to downgrade the quality of evidence due to imprecision.

² Sparse data: only 93 events observed

³ Sparse data: only 44 events observed



Trusted evidence. Informed decisions. Better health.



BACKGROUND

Crohn's disease is an inflammatory condition of unknown etiology that can affect any portion of the gastrointestinal tract from the mouth to the perianal area. However, it most commonly involves the distal small bowel and/or colon. Its transmural inflammatory nature coupled with the variability of organ distribution gives rise to a spectrum of clinical presentations, each of which has to be considered separately in deciding upon the proper therapeutic approach (Farrell 1989):

- Mild to moderate Crohn's disease Ambulatory patients able to tolerate an oral diet without dehydration, toxicity, abdominal tenderness, mass, or obstruction;
- Moderate to severe Crohn's disease Patients who have failed treatment for mild to moderate disease or patients with prominent symptoms such as fever, weight loss, abdominal pain and tenderness, intermittent nausea or vomiting, or anemia;
- Severe-fulminant disease Patients with persisting symptoms despite treatment with steroids or patients presenting with high fever, persistent vomiting, intestinal obstruction, rebound tenderness, cachexia, or an abscess; and
- Remission Patients who are asymptomatic either spontaneously or after medical or surgical intervention. Patients requiring steroids to remain asymptomatic are not considered to be in remission.

The exact cause of Crohn's disease remains unknown. Nevertheless it is apparent that inflammation is associated with an imbalance between proinflammatory and anti-inflammatory cytokines produced within the intestinal mucosa. The intestinal mucosa persists in a state of controlled inflammation where proinflammatory cytokines (such as TNF-alpha, IL-1, IL-6, IL-8, and IL-12 are counterbalanced by anti-inflammatory cytokines (such as IL-4, IL-10, IL-11 and IL-13; Korzenik 2006).

Interleukin (IL)-10 is a cytokine that has antiinflammatory and immunosuppressant properties. Endogenous expression of IL-10 is increased in the inflamed mucosa from patients with inflammatory bowel disease (Autschbach 1998). It regulates mucosal inflammation by inhibiting T-cell/macrophage activation and proinflammatory cytokine synthesis. IL-10 acts to suppress inflammation resulting from both antigen-specific and innate immune responses by reducing: monocyte HLA class-II expression, T-cell secretion of IL-2 and interferon, activated monocyte production of IL-1, IL-6, IL-8, TNF-alpha, and granulocytemacrophage colony-stimulating factor. IL-10 also upregulates the production of IL-1 receptor antagonist by monocytes (Van Deventer 1997, Fedorak 2000).

Medical therapy for Crohn's disease, using agents such as corticosteroids, immunosuppressives, and 5-aminosalicylates often does not control the disease. Thus, newer approaches to therapy are being evaluated (Korzenik 2006).

Because Crohn's disease represents a state of dysregulated inflammation, drugs that can augment the anti-inflammatory response have the potential to downregulate inflammation and thereby improve the disease. Recombinant human interleukin 10 is identical to endogenous human interleukin 10 with the exception of a methionine residue at the amino terminus (Fedorak 2000, Schreiber 2000). Recombinant human interleukin 10 (Tenovil:

Schering-Plough Research Institute, Kenilworth, NJ) comes in a sterilised, lyophilised white powder form containing sodium citrate, sucrose and glycerine. Prior to use, the drug is reconstituted with sterile water to a clear colourless solution.

The potential benefit of recombinant IL-10 in Crohn's disease was first demonstrated in a pilot study in which 46 patients with active, steroid-resistant Crohn's disease were randomized to varying doses of IL-10 or placebo administered once daily intravenously for seven consecutive days (Van Deventer 1997). Following treatment, the average score on the Crohn's disease activity index was lower among patients receiving active treatment (179 versus 226), although results were not statistically significant. Recent trials of cytokine and anticytokine therapies have demonstrated that manipulations of T-cell and macrophage-derived cytokines may provide effective treatment for Crohn's disease.

OBJECTIVES

The primary objectives were to determine the efficacy and safety of recombinant human interleukin 10 (IL-10) for induction of remission in Crohn's disease.

METHODS

Criteria for considering studies for this review

Types of studies

Randomized controlled trials comparing recombinant human interleukin 10 to placebo or a control therapy were considered for inclusion.

Types of participants

Patients of any age with active Crohn's disease (Crohn's disease activity index 'CDAI' >150) defined by conventional clinical, radiological and endoscopic criteria were considered for inclusion.

Types of interventions

Trials comparing recombinant human interleukin 10 versus placebo or an active control therapy were considered for inclusion.

Types of outcome measures

The primary outcome for the review was the rate of patients achieving remission as defined by the primary studies, and expressed as a percentage of the patients randomized (intention to treat analysis). For the purposes of this review, a complete remission was defined as a CDAI of less than or equal to 150 points, with a decrease of at least 100 points from baseline.

Secondary outcome measures included: changes in the mean CDAI, rate of patients achieving a clinical remission (CDAI of less than or equal to 150 points), adverse events, severe adverse events, serious adverse events and withdrawal because of adverse events.

Search methods for identification of studies

Electronic searches

A computer assisted search of the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane IBD/FBD Review Group Specialized Trials Register was performed. In addition the on-line databases MEDLINE and EMBASE were searched up to September 2010. The medical subject heading (MeSH)

Cochrane Library

terms "Crohn disease" or "inflammatory bowel disease" and "interleukin" were used to perform key word searches of each database.

Searching other resources

Manual searches of reference lists from potentially relevant papers were performed to identify additional studies. Abstracts from major gastroenterological meetings were searched to identify research submitted in abstract form only. Personal contacts and leaders in the field were contacted to identify other studies which may not be published. The manufacturer of rhIL-10 (SCH 52000 or Tenovil, Schering Plough, Kelinworth, NJ, USA) was contacted for additional studies with no success.

Data collection and analysis

Selection of studies

All publications identified by the search strategy were assessed independently by two authors (FB and PAC), and relevant studies selected according to the inclusion criteria. Any disagreement among authors was resolved by consensus. When insufficient information was provided to determine the risk of bias from the original report authors were contacted to confirm the method of randomization and allocation concealment.

Data extraction and management

Two authors (FB and PAC) independently extracted data using a data extraction form. Any disagreement among authors was resolved by consensus.

Assessment of risk of bias in included studies

Two authors (FB and PAC) independently assessed the risk of bias of the included trials using the criteria described in the Cochrane Reviewer's Handbook (Higgins 2008). A third author (IS) checked the assessment for accuracy. The risk of bias of the included trials is detailed in the Characteristics of included studies tables.

The adequacy of the methods used to generate the allocation sequence; the concealment of allocation; and blinding (clinician, participant outcome assessor) were assessed. For each trial, the risk of bias was classified as high or low or unclear if there was an insufficient description in the original reports. Overall, a trial was considered to be at low risk of bias if allocation concealment and blinding of participants were adequate.

The generation of the allocation sequence was judged to be adequate only if the method used for the allocation sequence generation was sufficiently described (e.g., number tables generated by computer), and inadequate for those systems involving dates, names, or hospital record numbers for the allocation of patients. Allocation concealment was judged to be adequate if the allocation of patients involved a central or independent randomisation, identically numbered packages prepared at independent offices, or sealed and opaque envelopes. Methods for which investigators could know the assignment of patients were judged to be inadequate. Methods that ensured the blinding of participants, investigators and outcome assessors were judged to be adequate. Open trials or those methods that did not blind participants or investigators, were judged as inadequate. Follow up was judged to be adequate if the numbers and reasons for drop-outs and withdrawals in all intervention groups were described or if it was specified that there were no drop-outs or withdrawals.

The overall quality of the evidence was assessed using the GRADE approach. The GRADE approach rates the overall quality of the evidence as high, moderate, low or very low and takes several dimensions into account including design and execution, consistency, directness, precision and, publication and reporting bias (Guyatt 2008). The findings of the GRADE analysis are included in the summary of findings table.

Data synthesis

Data were analyzed using Review Manager (RevMan 5). All data were analyzed on an intention-to-treat basis. Data were extracted from the original research articles and converted into 2x2 tables. Heterogeneity among studies was assessed using the chi-square test and the l² statistic. As the chi-square test has low power in the situation of a meta-analysis, when trials have a small sample size or are few in number, a P-value of 0.10 was regarded as statistically significant. For pooled data, summary test statistics was derived using the relative risk ratio and 95% confidence intervals. A random effects model was used for pooling data. The definitions of treatment success, remission and clinical improvement was set by the authors of each paper, and data were combined for analysis only if these definitions were sufficiently similar (determined by consensus).


RESULTS

Description of studies

Six hundred and fifty-one citations were identified by the electronic search, from which 12 studies were considered potentially eligible for inclusion (Figure 1). Nine studies were excluded after analysing their full text (see Characteristics of excluded studies; Colombel 2001, de Villiers 2003, Dejaco 1998, Geier 2007, Schreiber 2002, Tilg 1998a, Tilg 1998b, Tilg 2002a, Tilg 2002b). The reasons for exclusion included: different inclusion criteria than the review (patients, interventions or outcomes), different type of study design or being a review or an editorial. The 3 remaining studies fulfilled the eligibility criteria and were included in the review (Fedorak 2000; Schreiber 2000; Van Deventer 1997).







Schreiber 2000 conducted a prospective, multicentre, doubleblind, placebo-controlled study in 329 therapy-refractory patients with Crohn's disease. The trial assessed the effects on clinical improvement, and clinical remission of 4 different rhuIL-10 doses compared to placebo. The treatment was administrated subcutaneously over 28 days with a follow up period of 4 weeks.

Fedorak 2000 was a 24-week multicentre, prospective, randomised, double-blind, placebo-controlled, and sequential-escalating-dose study. Ninety-five patients with CDAI scores of 200 to 350 were enrolled and treated with 4 different doses of rhuIL-10 subcutaneously or placebo once daily for 28 consecutive days. After the treatment period the patients were followed up to 20 weeks. The primary outcomes were safety and tolerance, and efficacy (defined as clinical remission) was a secondary outcome.

Van Deventer 1997 reported a double-blind randomised multicentre trial to evaluate the safety, tolerance, and pharmacokinetics of IL-10 in Crohn's disease. Forty-six patients


with active steroid resistant Crohn's disease were treated with one of five doses of rhuIL-10 or placebo administered once daily by intravenous bolus injection over 7 consecutive days. There was a 3 week follow up period.

Risk of bias in included studies

No major limitations in the design and execution of the trials included in the review were identified (See Figure 2). Although there were some concerns about a lack of information about the procedures used to generate the randomisation sequences (only Fedorak 2000 reported adequate data on this domain in the trial report) additional information was obtained from a researcher involved in Van Deventer 1997 and Schreiber 2000 studies confirming that the randomisation sequence was computer generated. All the trials reported adequate allocation concealment procedures. The three included trials adequately blinded investigators and patients, but procedures for outcome assessment were unclear.



Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



The three included trials reported data on exclusions or losses from follow up. This could have an impact for the Schreiber 2000 study, that failed to detail the reason of discontinuation for 45 patients from the originally 329 randomised.

Effects of interventions

See: Summary of findings for the main comparison IL-10 compared to placebo for induction of remission in Crohn's disease

Complete remission

There was no statistically significant difference in the number of complete remissions in patients that received interleukin 10 compared to placebo (79 events, 3 trials; RR 1.43; 95% CI 0.62 to 3.29). The results reported in the studies were moderately variable ($l^2=40\%$; Figure 3).

Figure 3. Forest plot of comparison: 1 IL-10 vs placebo, outcome: 1.4 Complete remission all doses (CDAI < 150 with a decrease in CDAI of at least 100 points from baseline).

	IL-10	0	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Fedorak 2000	9	72	0	23	8.0%	6.25 [0.38, 103.36]	
Schreiber 2000	40	263	11	66	56.6%	0.91 [0.50, 1.68]	
Van Deventer 1997	16	33	3	13	35.4%	2.10 [0.73, 6.02]	+
Total (95% CI)		368		102	100.0%	1.43 [0.62, 3.29]	-
Total events	65		14				
Heterogeneity: Tau² =	= 0.22; Ch	i ^z = 3.3	2, df = 2 ((P = 0.1	9); l² = 40	%	
Test for overall effect:	Z=0.84	(P = 0.4	40)				Favours control Favours experimenta

Clinical remission

There was no statistically significant difference in the number of clinical remissions in patients receiving interleukin 10 compared

with placebo (93 events; 3 trials; RR 1.29; 95% Cl 0.79 to 2.11). The results reported in the studies were homogeneous ($I^2=0\%$; Figure 4).

Figure 4. Forest plot of comparison: 1 IL-10 vs placebo, outcome: 1.5 Clinical remision (CDAI < 150).

	IL-10	D	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Fedorak 2000	11	72	0	23	3.1%	7.56 [0.46, 123.56]	
Schreiber 2000	57	263	12	66	77.4%	1.19 [0.68, 2.09]	
Van Deventer 1997	10	33	3	13	19.5%	1.31 [0.43, 4.02]	
Total (95% CI)		368		102	100.0%	1.29 [0.79, 2.11]	•
Total events	78		15				
Heterogeneity: Tau² =	= 0.00; Ch	i² = 1.7	5, df = 2 ((P = 0.4	2); I² = 0 9	6	
Test for overall effect:	Z=1.00	(P = 0.3	32)				Favours control Favours experimenta

Adverse events

Adverse events were reported differently across studies including: serious adverse events, severe adverse events, any adverse events and withdrawals due to adverse events. Additionally the studies provided detail about the type of complications.

Although serious adverse (99 events, 1 trial) events were more frequent in the IL-10 group compared to placebo, the difference was not statistically significant (RR 1.13; 95%CI 0.73 to 1.74; Figure 5). There were no statistically significant differences in the proportion of patients who experienced any adverse event (395 events, 3 trials; RR 1.00; 95% CI 0.94 to 1.06; I²=0%; Figure 6).

Patients receiving IL-10 were significantly more likely than placebo patients to withdraw from the studies due to adverse events (44 events, 2 trials; RR 13.50; 95% CI 3.89 to 46.79; $I^2=0\%$; Analysis 1.5). Eighteen patients treated with interleukin 10 experienced thrombocytopenia compared to no placebo patients, but the difference was not statistically significant (RR 4.73; 95% CI 0.63 to 35.33; $I^2=0\%$; Analysis 1.6). Severe adverse events (105 events, 3 trials) were more frequently reported in patients receiving interleukin 10 than those receiving placebo, but the difference was not statistically significant (RR 0.88; 95% CI 0.37 to 2.12, $I^2=63\%$; Analysis 1.7).

Figure 5. Forest plot of comparison: 1 IL-10 vs placebo, outcome: 1.3 Serious adverse events.

	IL-1(D	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Schreiber 2000	81	263	18	66	100.0%	1.13 [0.73, 1.74]	
Total (95% CI)		263		66	100.0%	1.13 [0.73, 1.74]	
Total events	81		18				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 0.55 ((P = 0.5	58)			F	0.5 0.7 1 1.5 2 Favours experimental Favours control

Figure 6. Forest plot of comparison: 1 IL-10 vs placebo, outcome: 1.7 Any adverse event.

IL-10)	Place	bo		Risk Ratio	Risk Ratio
Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
63	72	21	23	16.3%	0.96 [0.82, 1.12]	
249	263	62	66	83.7%	1.01 [0.94, 1.08]	
	335		89	100.0%	1.00 [0.94, 1.06]	◆
312		83				
			P = 0.5	5); I² = 0%	6	0.5 0.7 1 1.5 2 Favours control Favours experimenta
	Events 63 249 312 : 0.00; Chi	63 72 249 263 335 312 0.00; Chi ² = 0.3	Events Total Events 63 72 21 249 263 62 335 312 83	Events Total Events Total 63 72 21 23 249 263 62 66 335 89 312 83 0.00; Chi² = 0.36, df = 1 (P = 0.5	Events Total Events Total Weight 63 72 21 23 16.3% 249 263 62 66 83.7% 335 89 100.0% 312 83 0.00; Chi² = 0.36, df = 1 (P = 0.55); I² = 0%	Events Total Events Total Weight M-H, Random, 95% Cl 63 72 21 23 16.3% 0.96 [0.82, 1.12] 249 263 62 66 83.7% 1.01 [0.94, 1.08] 335 89 100.0% 1.00 [0.94, 1.06] 312 83

DISCUSSION

Summary of main results

This systematic review about the use of interleukin 10, compared with placebo, for induction of remission in Crohn's disease identified three trials with a total of 470 patients. These trials were



conducted between 1997 and 2000. The pooled results show that this drug does not increase the number of remissions (complete or clinical) compared to placebo. The use of interleukin 10 resulted in a significantly increased number of patients withdrawing due to adverse events. There were no statistically significant differences in the proportions of patients who experienced serious or any adverse events.

Quality of the evidence

The overall quality of the evidence according to the GRADE approach is moderate. This is due to imprecision of the available results. This imprecision is due to the low number of events (always under 100 events).

Potential biases in the review process

Efforts to locate unpublished studies might make publication bias less likely. However, given that the three trials are negative it seems unlikely that positive trials remain unpublished.

AUTHORS' CONCLUSIONS

Implications for practice

Interleukin 10, compared with placebo, does not show any benefit for the treatment of active Crohn's disease, showing an

unfavourable balance between the potential benefits and adverse events. This systematic review showed that interleukin 10 does not increase the number of remissions, complete or clinical, but significantly increases the number of withdrawals due to adverse events. The quality of the evidence regarding the efficacy of IL-10 is moderate.

Implications for research

Although further research may have an impact on point estimates, future trials are unlikely to be undertaken.

ACKNOWLEDGEMENTS

Pablo Alonso-Coello is funded by a Miguel Servet investigator contract by the Instituto de Salud Carlos III (CP09/00137).

Funding for the IBD/FBD Review Group (September 1, 2010 - August 31, 2015) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch (CON - 105529) and the CIHR Institutes of Nutrition, Metabolism and Diabetes (INMD); and Infection and Immunity (III).

Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.

REFERENCES

References to studies included in this review

Fedorak 2000 {published data only}

Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately severe active Crohns disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. *Gastroenterology* 2000;**119**(6):1473-82.

Schreiber 2000 {published data only}

Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. *Gastroenterology* 2000;**19**(6):1461-72.

Van Deventer 1997 {published data only}

Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. *Gastroenterology* 1997;**113**(2):383-9.

References to studies excluded from this review

Colombel 2001 {published data only}

Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. *Gut* 2001;**49**(1):42-6.

de Villiers 2003 {published data only}

de Villiers WJ. Crohn's disease and IL-10 therapy: promise regained. *Inflamm Bowel Dis* 2003;**9**(3):210-1.

Dejaco 1998 {published data only}

Dejaco C, Tilg H, Gasche C. In vivo changes of lymphocyte subpopulations and leukocyte surface markers by multiple doses of recombinant human interleukin-10 in inflammatory bowel disease. *Gastroenterology* 1998;**114**(Suppl 1):A961.

Geier 2007 {published data only}

Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. *Int J Food Microbiol* 2007;**115**(1):1-11.

Schreiber 2002 {published data only}

Schreiber S. Novel and future strategies in the management of IBD. *Annals of Gastroenterology* 2002;**15**(4):307.

Tilg 1998a {published data only}

Tilg H, Kaser A, Schreiber S, Gregor M, Rutgeerts P, van Deventer S, et al. New insights into the pathogenesis of

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

anemia of chronic diseases: induction of ferritin synthesis and development of anemia during recombinant human interleukin-10 (rHuIL-10) treatment of chronic active Crohn's disease (CACD). *Gastroenterology* 1998;**114**(Suppl 1):A1100.

Tilg 1998b {published data only}

Tilg H, Kaser A, Propst A, Schreiber S, Gregor M, Rutgeerts P, et al. Recombinant human interleukin-10 (rHuIL-10) therapy in steroid-refractory chronic active Crohns disease (CACD): induction of neopterin, a degradation product of the pteridine pathway regulated by interferon-gamma. *Gastroenterology* 1998;**114**(Suppl 1):A1100.

Tilg 2002a {published data only}

Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. *Gut* 2002;**50**(2):191-5.

Tilg 2002b {published data only}

Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. *J Immunol* 2002;**169**(4):2204-9.

Additional references

Autschbach 1998

Autschbach F, Braunstein J, Helmke B, Zuna I, Schumann G, Niemir ZI, et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. *Am J Pathol* 1998;**153**(1):121-30.

Farrell 1989

Farrell RJ, Peppercorn MA. Medical management of Crohn's disease in adults. *Am J Gastroenterol* 1989;**84**:249.

Guyatt 2008

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;**336**(7650):924-6.

Higgins 2008

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1[updated September 2008]. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd, 2008.

Korzenik 2006

Joshua R Korzenik, Daniel K Podolski. Evolving knowledge and therapy of inflammatory bowel disease. *Nature Reviews* 2006;**5**:197-209.

Fedorak 2000	
Methods	Multicenter, double-blind, placebo controlled, randomised clinical trial
	July 1995 - December 1996
Participants	N = 95, Age: > 18
	Diagnosis: Mild to moderate active Crohn's disease, CDAI = 200-350, (not presently receiving corticos- teroids, mesalamine or immunosuppressive therapy)
Interventions	Intervention: 72 patients received s.c. rhulL-10 (1, 5 10, 20 ųg/kg) once daily (OD)
	Control: 23 patients received placebo OD
	Duration: 28 days treatment + 20 week follow-up period
Outcomes	Primary outcomes:
	1. Safety and tolerance. Each clinical adverse event was graded for severity at each visit.
	Secondary outcomes:
	1. Efficacy:
	Complete remission, defined as a CDAI at day 29 lower than or equal to 150 points and a decrease from baseline in CDAI of more than 100 points, plus improvement or resolution in endoscopic appearance.
	Quality of life, measured by the IBD questionnaire
	2. IL-10 pharmacokinetics

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Quote: 'Computer generated randomisation schedules [] at a 3:1 ratio'
Allocation concealment (selection bias)	Low risk	Independent central randomisation
Blinding (performance bias and detection bias) All outcomes	Low risk	Quote: 'rhulL-10 [] was reconstituted with sterile water to a clear, colourless solution. Placebo of the same formulation, minus the active ingredient, was identical in appearance.'
Incomplete outcome data	Low risk	Intention to treat sample:
(attrition bias) All outcomes		95 patients (72 in rhulL-10 group and 23 to placebo).
		Per protocol sample:
		12 patients (10 from the rhulL-10 group and 2 from the placebo group) did not complete the 28-day treatment phase, for the following reasons:
		Adverse effects: 6 ųg/kg rhulL-10 patients
		Treatment failure: 3 ųg/kg rhuIL-10 versus 2 placebo
		Patient preferences: 1 ųg/kg rhulL-10 patient



Schreiber 2000

Methods	Multicenter, randomised, double-blind, placebo-controlled clinical trial
	February 1996 - October 1997
Participants	N = 329, Age: adults
	Diagnosis: therapy - refractory Crohn's disease
Interventions	Intervention: s. c., different doses of rhulL-10: 1 ųg/kg, 18% [9.6 - 29.2], 4 ųg/kg, 20% [11.3 - 32.2], 8 ųg/ kg, 20% [11.1 - 31.8], 20 ųg/kg, 28% [18 - 40.7]
	Control: placebo, 18% [9.6-29.6]
	Duration: 28 days
Outcomes	Primary outcomes:
	1. Clinical remission, defined as a CDAI score lower than 150 and a decrease from baseline CDAI of more than 100 points.
	Secondary outcomes:
	1. Clinical improvement, defined as a decrease from baseline CDAI of more than 100 points
	2 Endessonis improvement
	2. Endoscopic improvement
	3. Quality of life measured by IBD questionnaire and SF-36 health survey

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer generated sequence, as confirmed by a researcher involved in the execution of the trial, not described in the report (quote: 'patients were ran-domized').
		Stratification according to steroid dose received, and use of immunosuppres- sive agents.
Allocation concealment (selection bias)	Low risk	Quote: 'Central randomization was used,'
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blinding properly conducted, as confirmed by a researcher involved in the execution of the trial.
		After 50 patients completed the treatment safety was assessed in a blinded fashion by an independent data monitoring committee. After treatment of 151 efficacy was assessed in an unblinded fashion.
Incomplete outcome data	Unclear risk	329 patients were randomized (263 to rhulL-10 and 66 to placebo).
(attrition bias) All outcomes		45 patients discontinued the treatment for the following reasons (distribution by groups not reported):
		Adverse events: 30

Schreiber 2000 (Continued)

Treatment failure: 9

Ineligibility: 3 (these patients were randomised but did not receive the treatment)

Patient preference: 2

Death: 1

Van Deventer 1997

Risk of bias	
Notes	
	clinical remission, defined as a decrease from baseline CDAI of more than 100 points
	complete remission, defined as a CDAI score lower than 150 and a decrease from baseline CDAI of more than 100 points.
	1. Efficacy:
	Secondary outcomes:
	1. Safety and tolerance
Outcomes	Primary outcomes:
	Duration: 7 days + 3 week follow-up period
	Control: placebo identical in appearance and volume at each dose level
Interventions	Intervention: 1 of 5 doses of rhulL-10 (0.5, 1, 5, 10, 25 ųg/kg), i. v. bolus, once daily
	Diagnosis: active steroid -resistant Crohn's disease
Participants	N = 46, Age: 18-65 years
	December 1994 - June 1995
Methods	Multicentre, double-blind, placebo-controlled randomised clinical trial

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Low risk	Computer generated sequence, as confirmed by a researcher involved in the execution of the trial, not described in the report (quote: 'patients were ran- domized').
		Randomization established different ratios depending of the IL 10 dose.
Allocation concealment (selection bias)	Low risk	Central randomization
Blinding (performance bias and detection bias) All outcomes	Low risk	IL 10 was provided as a sterile powder and reconstituted with sterile water. Placebo was identical in appearance and volume at each dose level.
Incomplete outcome data (attrition bias) All outcomes	Low risk	46 patients randomized (33 IL10 vs 13 placebo)



Van Deventer 1997 (Continued)

One patient allocated to placebo received a single dose of IL10, and was withdrawn (excluded for the efficacy analysis)

One patient on placebo discontinued the study due to abdominal pain.

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Colombel 2001	Did not fit with our inclusion criteria: different patients. The study assessed the role of IL-10 in pre- venting post-operative recurrence of Crohn's disease
de Villiers 2003	Did not fit with our inclusion criteria: different patients. This was a selected summary of a study of IL-10 in mice
Dejaco 1998	Did not fit with our inclusion criteria: different patients. <i>In vivo</i> study of patients with Crohn's dis- ease or ulcerative colitis
Geier 2007	Review
Schreiber 2002	Editorial
Tilg 1998a	Non-RCT
Tilg 1998b	Did not fit with our inclusion criteria: different outcomes of interest
Tilg 2002a	Did not fit with our inclusion criteria: different outcomes of interest
Tilg 2002b	Did not fit with our inclusion criteria: different outcomes of interest

DATA AND ANALYSES

Comparison 1. IL-10 vs placebo

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Complete remission (CDAI<150 with a decrease in CDAI of at least 100 points from baseline)	3	470	Risk Ratio (M-H, Random, 95% CI)	1.43 [0.62, 3.29]
2 Clinical remision (CDAI<150)	3	470	Risk Ratio (M-H, Random, 95% CI)	1.29 [0.79, 2.11]
3 Serious adverse events	1	329	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.73, 1.74]
4 Any adverse event	2	424	Risk Ratio (M-H, Random, 95% CI)	1.00 [0.94, 1.06]



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
5 Withdrawals due to adverse events	2	228	Risk Ratio (M-H, Random, 95% CI)	13.50 [3.89, 46.79]
6 Thrombocytopenia	2	424	Risk Ratio (M-H, Random, 95% CI)	4.73 [0.63, 35.33]
7 Severe adverse events	3	470	Risk Ratio (M-H, Random, 95% CI)	0.88 [0.37, 2.12]

Analysis 1.1. Comparison 1 IL-10 vs placebo, Outcome 1 Complete remission (CDAI<150 with a decrease in CDAI of at least 100 points from baseline).

Study or subgroup	IL-10	Placebo			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Random, 95%	СІ			M-H, Random, 95% CI
Fedorak 2000	9/72	0/23					\rightarrow	7.96%	6.25[0.38,103.36]
Schreiber 2000	40/263	11/66						56.64%	0.91[0.5,1.68]
Van Deventer 1997	16/33	3/13			+			35.4%	2.1[0.73,6.02]
Total (95% CI)	368	102			-			100%	1.43[0.62,3.29]
Total events: 65 (IL-10), 14 (Plac	ebo)								
Heterogeneity: Tau ² =0.22; Chi ² =	-3.32, df=2(P=0.19); I ² =39.8	2%							
Test for overall effect: Z=0.84(P=	=0.4)								
		Favours control	0.01	0.1	1	10	100	Favours experimental	

Analysis 1.2. Comparison 1 IL-10 vs placebo, Outcome 2 Clinical remision (CDAI<150).

Study or subgroup	IL-10	Placebo		Risk Ratio		Weight	Risk Ratio
	n/N	n/N	N	1-H, Random, 95% Cl			M-H, Random, 95% CI
Fedorak 2000	11/72	0/23			\rightarrow	3.12%	7.56[0.46,123.56]
Schreiber 2000	57/263	12/66		- <mark></mark> -		77.43%	1.19[0.68,2.09]
Van Deventer 1997	10/33	3/13				19.45%	1.31[0.43,4.02]
Total (95% CI)	368	102		•		100%	1.29[0.79,2.11]
Total events: 78 (IL-10), 15 (Plac	cebo)						
Heterogeneity: Tau ² =0; Chi ² =1.	75, df=2(P=0.42); I ² =0%						
Test for overall effect: Z=1(P=0.	32)				1		
		Faure as at a l	0.01 0	1 10	100	Farmer and a state at a	

 Favours control
 0.01
 0.1
 1
 10
 100
 Favours experimental

Analysis 1.3. Comparison 1 IL-10 vs placebo, Outcome 3 Serious adverse events.

Study or subgroup	IL-10	Placebo			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Random, 95	5% CI			M-H, Random, 95% Cl
Schreiber 2000	81/263	18/66				1		100%	1.13[0.73,1.74]
	Favou	irs experimental	0.5	0.7	1	1.5	2	Favours control	



Study or subgroup	IL-10	Placebo			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		М-Н, Р	Random, 9	5% CI			M-H, Random, 95% CI
Total (95% CI)	263	66						100%	1.13[0.73,1.74]
Total events: 81 (IL-10), 18 (Placebo)									
Heterogeneity: Not applicable									
Test for overall effect: Z=0.55(P=0.58)									
	Fav	ours experimental	0.5	0.7	1	1.5	2	Favours control	

Analysis 1.4. Comparison 1 IL-10 vs placebo, Outcome 4 Any adverse event.

Study or subgroup	IL-10	Placebo			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Random, 95%	CI			M-H, Random, 95% Cl
Fedorak 2000	63/72	21/23			-+			16.28%	0.96[0.82,1.12]
Schreiber 2000	249/263	62/66			-			83.72%	1.01[0.94,1.08]
Total (95% CI)	335	89			•			100%	1[0.94,1.06]
Total events: 312 (IL-10), 83 (Place	00)								
Heterogeneity: Tau ² =0; Chi ² =0.36, o	df=1(P=0.55); I ² =0%								
Test for overall effect: Z=0.01(P=0.9	99)								
		Favours control	0.5	0.7	1	1.5	2	Favours experimenta	l

Analysis 1.5. Comparison 1 IL-10 vs placebo, Outcome 5 Withdrawals due to adverse events.

Study or subgroup	IL-10	Placebo			Risk Ratio	,		Weight	Risk Ratio
	n/N	n/N		М-Н, Я	andom, 9	5% CI			M-H, Random, 95% Cl
Fedorak 2000	6/72	0/23		_		+	_	19.17%	4.27[0.25,73.1]
Schreiber 2000	36/67	2/66						80.83%	17.73[4.45,70.67]
Total (95% CI)	139	89						100%	13.5[3.89,46.79]
Total events: 42 (IL-10), 2 (Placebo)									
Heterogeneity: Tau ² =0; Chi ² =0.78, df=	1(P=0.38); I ² =0%								
Test for overall effect: Z=4.1(P<0.0001)								
	F	avours treatment	0.01	0.1	1	10	100	Favours control	

Analysis 1.6. Comparison 1 IL-10 vs placebo, Outcome 6 Thrombocytopenia.

Study or subgroup	IL-10	Placebo			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Random, 9	5% CI			M-H, Random, 95% CI
Fedorak 2000	4/72	0/23						48.62%	2.96[0.17,52.98]
Schreiber 2000	14/263	0/66						51.38%	7.36[0.44,121.81]
Total (95% CI)	335	89					-	100%	4.73[0.63,35.33]
Total events: 18 (IL-10), 0 (Placebo)									
Heterogeneity: Tau ² =0; Chi ² =0.21, df=	1(P=0.65); I ² =0%								
Test for overall effect: Z=1.51(P=0.13)									
	Favo	urs experimental	0.01	0.1	1	10	100	Favours control	



Analysis 1.7. Comparison 1 IL-10 vs placebo, Outcome 7 Severe adverse events.

Study or subgroup	IL-10	Placebo			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Random, 9	5% CI			M-H, Random, 95% Cl
Fedorak 2000	6/72	4/23						27.28%	0.48[0.15,1.55]
Schreiber 2000	74/263	11/66						43.46%	1.69[0.95,2.99]
Van Deventer 1997	6/33	4/13		-				29.26%	0.59[0.2,1.76]
Total (95% CI)	368	102			•			100%	0.88[0.37,2.12]
Total events: 86 (IL-10), 19 (Placebo)									
Heterogeneity: Tau ² =0.38; Chi ² =5.37, d	lf=2(P=0.07); I ² =62.7	7%							
Test for overall effect: Z=0.28(P=0.78)									
	Favo	urs experimental	0.01	0.1	1	10	100	Favours control	

WHAT'S NEW

Date	Event	Description
30 November 2011	Amended	Updated contact details for first author

CONTRIBUTIONS OF AUTHORS

Drs Buruiana and Alonso-Coello screened and appraised the quality of published papers, abstracted data from included studies, communicated with investigators regarding unpublished data, interpreted the analyses, and wrote the review. Ivan Solà performed the search, interpreted the analysis, developed the Summary of Findings table and provided important intellectual comments to the different review drafts.

DECLARATIONS OF INTEREST

None declared.

SOURCES OF SUPPORT

Internal sources

• Iberoamerican Cochrane Centre, Spain.

External sources

• No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

For the sake of improving understanding and communication of results our final analysis included a calculation of risk ratios instead of odds ratios. We use a random effect model instead of a fixed effect due to its more conservative estimation of treatment effects. Given the recent changes in the evaluation of the quality of the included studies in the handbook and in the international literature in general we analysed the risk of bias and additionally used the GRADE system for the overall quality of the evidence.

INDEX TERMS

Medical Subject Headings (MeSH)

Crohn Disease [*drug therapy]; Interleukin-10 [*therapeutic use]; Patient Dropouts [statistics & numerical data]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]; Remission Induction



MeSH check words

Humans